<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01982786</url>
  </required_header>
  <id_info>
    <org_study_id>PR15</org_study_id>
    <nct_id>NCT01982786</nct_id>
  </id_info>
  <brief_title>Feasibility Trial Of Image Guided External Beam Radiotherapy With Or Without High Dose Rate Brachytherapy Boost In Men With Intermediate-Risk Prostate Cancer</brief_title>
  <official_title>Randomized Phase II Feasibility Trial Of Image Guided External Beam Radiotherapy With Or Without High Dose Rate Brachytherapy Boost In Men With Intermediate-Risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canadian Cancer Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done because investigators involved in this study would like to&#xD;
      compare image guided external beam radiation therapy (IGRT) to IGRT plus HDR brachytherapy&#xD;
      boost to see which treatment is better and what the side effects of treatment are.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before a big study is done, a smaller study (called a &quot;feasibility study&quot;) is required to&#xD;
      make sure that patients and physicians are willing to participate in a study comparing the&#xD;
      two kinds of treatments, and to verify how the radiation therapy is given in different&#xD;
      centres across Canada.&#xD;
&#xD;
      The standard or usual treatment for this disease includes treatment with IGRT or IGRT plus&#xD;
      HDR brachytherapy boost.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 5, 2013</start_date>
  <completion_date type="Actual">October 19, 2018</completion_date>
  <primary_completion_date type="Actual">July 5, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of Ability to Accrue Patients</measure>
    <time_frame>21 months</time_frame>
    <description>The ability to accrue 60 patients over an 18 month period to a study that randomizes men with intermediate-risk prostate cancer to curative intent treatment with image guided external beam radiotherapy (IGRT) or IGRT with high dose rate (HDR) brachytherapy boost within a Canadian multicentre setting.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reported Adverse Events</measure>
    <time_frame>21 months</time_frame>
    <description>Acute genitourinary (GU) and gastrointestinal (GI) adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Compliance</measure>
    <time_frame>21 months</time_frame>
    <description>Treatment compliance will be monitored on an ongoing basis by Central Office and the designated radiotherapy quality assurance reviewer and will be described for both arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiotherapy Quality Assurance -Timing</measure>
    <time_frame>5 months</time_frame>
    <description>The time from the the time from IGRT Real Time Review Signed to IGRT Real Time Review Uploaded.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IGRT* 60 Gy in 20 fractions OR IGRT 78 Gy in 39 fractions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IGRT 37.5 Gy in 15 fractions&#xD;
+ HDR brachytherapy boost 15 Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Image guided external beam radiotherapy with or without brachytherapy boost</intervention_name>
    <description>image guided external beam radiotherapy (IGRT) or IGRT with high dose rate (HDR) brachytherapy boost</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Brachytherapy</intervention_name>
    <description>Brachytherapy boost</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed prostate adenocarcinoma. The date of the last biopsy that&#xD;
             verifies that the eligibility criterions have been met must be within 9 months prior&#xD;
             to randomization. There must be no prior treatment.&#xD;
&#xD;
          -  Intermediate-risk cancer patients based on the NCCN Guidelines (www.nccn.org):&#xD;
&#xD;
             • TNM classification:&#xD;
&#xD;
          -  T2b-T2c and Gleason Score &lt; 8/10 and PSA &lt; 20 ng/ml; or&#xD;
&#xD;
          -  T1c-T2a and Gleason Score 7/10 and PSA &lt; 20 ng/ml; or&#xD;
&#xD;
          -  T1c-T2a and Gleason Score ≤ 6/10 and 10 ≤ PSA &lt; 20 ng/ml&#xD;
&#xD;
        For patients who have been on alpha reductase inhibitors within the last 6 months, use the&#xD;
        following guidelines:&#xD;
&#xD;
          -  T2b-T2c and Gleason Score &lt; 8/10 and PSA ≤ 10 ng/ml; or&#xD;
&#xD;
          -  T1c-T2a and Gleason Score 7/10 and PSA ≤ 10 ng/ml; or&#xD;
&#xD;
          -  T1c-T2a and Gleason Score ≤ 6/10 and 5 ≤ PSA ≤ 10 ng/ml&#xD;
&#xD;
          -  No alpha reductase inhibitors (i.e. avodart, proscar) use within 2 weeks of&#xD;
             randomization. A washout period of 2 weeks is required prior to randomization.&#xD;
&#xD;
          -  Prostate volume ≤ 75 cc.&#xD;
&#xD;
          -  American Urological Association (AUA) Symptom Index score &lt; 20.&#xD;
&#xD;
          -  Judged to be medically fit for IGRT and HDR brachytherapy boost by a radiation&#xD;
             oncologist.&#xD;
&#xD;
          -  ECOG Performance Status of 0 or 1.&#xD;
&#xD;
          -  ≥ 18 years of age.&#xD;
&#xD;
          -  Patient consent must be appropriately obtained in accordance with applicable local and&#xD;
             regulatory requirements. Each patient must sign a consent form prior to enrolment in&#xD;
             the trial to document their willingness to participate.&#xD;
&#xD;
          -  Patients must be accessible for treatment and follow-up. Patients registered on this&#xD;
             trial must be treated and followed at the participating centre. This implies there&#xD;
             must be reasonable geographical limits (for example: 1 ½ hour's driving distance)&#xD;
             placed on patients being considered for this trial. Investigators must assure&#xD;
             themselves the patients registered on this trial will be available for complete&#xD;
             documentation of the treatment, adverse events, and follow-up.&#xD;
&#xD;
          -  Protocol treatment is to begin within 4 weeks of patient randomization. HDR&#xD;
             brachytherapy boost treatment is to begin within 3 weeks before or after IGRT for&#xD;
             those randomized to Arm 2.&#xD;
&#xD;
          -  Participants must be willing to take precautions to prevent pregnancy while on&#xD;
             treatment. In addition to routine contraceptive methods, &quot;effective contraception&quot;&#xD;
             also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with&#xD;
             a side-effect of pregnancy prevention). However, if at any point a previously celibate&#xD;
             patient chooses to become heterosexually active during the time period for use of&#xD;
             contraceptive measures, he is responsible for beginning contraceptive measures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of transurethral resection of the prostate (TURP).&#xD;
&#xD;
          -  Patients with a history of other malignancies, except: adequately treated non-melanoma&#xD;
             skin cancer, or other solid tumours curatively treated with no evidence of disease for&#xD;
             ≥ 5 years.&#xD;
&#xD;
          -  Prior or current bleeding diathesis.&#xD;
&#xD;
          -  Prior pelvic or prostate radiotherapy.&#xD;
&#xD;
          -  Previous history of (or planned) androgen deprivation therapy.&#xD;
&#xD;
          -  Evidence of metastatic disease.&#xD;
&#xD;
          -  Any serious active disease or co-morbid medical condition, laboratory abnormality,&#xD;
             psychiatric illness, active or uncontrolled infections, or serious illnesses or&#xD;
             medical conditions that would prevent the patient from participating or to be managed&#xD;
             according to the protocol (according to investigator's decision).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Vigneault</last_name>
    <role>Study Chair</role>
    <affiliation>CHUQ - Hotel Dieu de Quebec, Quebec QC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Douglas Loblaw</last_name>
    <role>Study Chair</role>
    <affiliation>Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto On</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. H. Bliss Murphy Cancer Centre</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Regional Health Centre</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6M2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeridge Health Oshawa</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odette Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Windsor Regional Cancer Centre</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 2X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Hopital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University - Dept. Oncology</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUQ-Pavillon Hotel-Dieu de Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Vigneault E, Morton G, Parulekar WR, Niazi TM, Springer CW, Barkati M, Chung P, Koll W, Kamran A, Monreal M, Ding K, Loblaw A. Randomised Phase II Feasibility Trial of Image-guided External Beam Radiotherapy With or Without High Dose Rate Brachytherapy Boost in Men with Intermediate-risk Prostate Cancer (CCTG PR15/ NCT01982786). Clin Oncol (R Coll Radiol). 2018 Sep;30(9):527-533. doi: 10.1016/j.clon.2018.05.007. Epub 2018 Jun 11.</citation>
    <PMID>29903505</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>November 6, 2013</study_first_submitted>
  <study_first_submitted_qc>November 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2013</study_first_posted>
  <results_first_submitted>March 30, 2017</results_first_submitted>
  <results_first_submitted_qc>September 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 22, 2020</results_first_posted>
  <last_update_submitted>September 29, 2020</last_update_submitted>
  <last_update_submitted_qc>September 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1</title>
          <description>IGRT* 60 Gy in 20 fractions OR IGRT 78 Gy in 39 fractions&#xD;
Image guided external beam radiotherapy with or without brachytherapy boost: image guided external beam radiotherapy (IGRT) or IGRT with high dose rate (HDR) brachytherapy boost</description>
        </group>
        <group group_id="P2">
          <title>Arm 2</title>
          <description>IGRT 37.5 Gy in 15 fractions&#xD;
+ HDR brachytherapy boost 15 Gy&#xD;
Image guided external beam radiotherapy with or without brachytherapy boost: image guided external beam radiotherapy (IGRT) or IGRT with high dose rate (HDR) brachytherapy boost&#xD;
Brachytherapy: Brachytherapy boost</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1</title>
          <description>IGRT* 60 Gy in 20 fractions OR IGRT 78 Gy in 39 fractions&#xD;
Image guided external beam radiotherapy with or without brachytherapy boost: image guided external beam radiotherapy (IGRT) or IGRT with high dose rate (HDR) brachytherapy boost</description>
        </group>
        <group group_id="B2">
          <title>Arm 2</title>
          <description>IGRT 37.5 Gy in 15 fractions&#xD;
+ HDR brachytherapy boost 15 Gy&#xD;
Image guided external beam radiotherapy with or without brachytherapy boost: image guided external beam radiotherapy (IGRT) or IGRT with high dose rate (HDR) brachytherapy boost&#xD;
Brachytherapy: Brachytherapy boost</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="57"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;= 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prostate Carcinoma Disease clinical T Stage</title>
          <description>Prostate Carcinoma Disease clinical T Stage, higher stage reprent worse disease</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>T1c</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2b</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2c</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PSA</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt; 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10-20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>The AUA Symptom Index Score</title>
          <description>The AUA Symptom Index Score, measures the bothersome the urinary symptoms. Higher value indicates of worse symptom.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>AUA score from 0 to 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUA score from 10 to 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>combined Gleason Score</title>
          <description>label the severity and stage of the prostate cancer, with higher value, the worse of the disease</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Gleason Score of 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Others</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>The ECOG Scale of Performance Status</title>
          <description>The ECOG Scale of Performance Status, 0 indicates Fully active, while 5 means dead.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Feasibility of Ability to Accrue Patients</title>
        <description>The ability to accrue 60 patients over an 18 month period to a study that randomizes men with intermediate-risk prostate cancer to curative intent treatment with image guided external beam radiotherapy (IGRT) or IGRT with high dose rate (HDR) brachytherapy boost within a Canadian multicentre setting.</description>
        <time_frame>21 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>IGRT* 60 Gy in 20 fractions OR IGRT 78 Gy in 39 fractions&#xD;
Image guided external beam radiotherapy with or without brachytherapy boost: image guided external beam radiotherapy (IGRT) or IGRT with high dose rate (HDR) brachytherapy boost</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>IGRT 37.5 Gy in 15 fractions&#xD;
+ HDR brachytherapy boost 15 Gy&#xD;
Image guided external beam radiotherapy with or without brachytherapy boost: image guided external beam radiotherapy (IGRT) or IGRT with high dose rate (HDR) brachytherapy boost&#xD;
Brachytherapy: Brachytherapy boost</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility of Ability to Accrue Patients</title>
          <description>The ability to accrue 60 patients over an 18 month period to a study that randomizes men with intermediate-risk prostate cancer to curative intent treatment with image guided external beam radiotherapy (IGRT) or IGRT with high dose rate (HDR) brachytherapy boost within a Canadian multicentre setting.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reported Adverse Events</title>
        <description>Acute genitourinary (GU) and gastrointestinal (GI) adverse events.</description>
        <time_frame>21 months</time_frame>
        <population>As treated population</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>IGRT* 60 Gy in 20 fractions OR IGRT 78 Gy in 39 fractions&#xD;
Image guided external beam radiotherapy with or without brachytherapy boost: image guided external beam radiotherapy (IGRT) or IGRT with high dose rate (HDR) brachytherapy boost</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>IGRT 37.5 Gy in 15 fractions&#xD;
+ HDR brachytherapy boost 15 Gy&#xD;
Image guided external beam radiotherapy with or without brachytherapy boost: image guided external beam radiotherapy (IGRT) or IGRT with high dose rate (HDR) brachytherapy boost&#xD;
Brachytherapy: Brachytherapy boost</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reported Adverse Events</title>
          <description>Acute genitourinary (GU) and gastrointestinal (GI) adverse events.</description>
          <population>As treated population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GASTROINTESTINAL DISORDERS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RENAL AND URINARY DISORDERS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Compliance</title>
        <description>Treatment compliance will be monitored on an ongoing basis by Central Office and the designated radiotherapy quality assurance reviewer and will be described for both arms.</description>
        <time_frame>21 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>IGRT* 60 Gy in 20 fractions OR IGRT 78 Gy in 39 fractions&#xD;
Image guided external beam radiotherapy with or without brachytherapy boost: image guided external beam radiotherapy (IGRT) or IGRT with high dose rate (HDR) brachytherapy boost</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>IGRT 37.5 Gy in 15 fractions&#xD;
+ HDR brachytherapy boost 15 Gy&#xD;
Image guided external beam radiotherapy with or without brachytherapy boost: image guided external beam radiotherapy (IGRT) or IGRT with high dose rate (HDR) brachytherapy boost&#xD;
Brachytherapy: Brachytherapy boost</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Compliance</title>
          <description>Treatment compliance will be monitored on an ongoing basis by Central Office and the designated radiotherapy quality assurance reviewer and will be described for both arms.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Minor Deviation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Deviation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Radiotherapy Quality Assurance -Timing</title>
        <description>The time from the the time from IGRT Real Time Review Signed to IGRT Real Time Review Uploaded.</description>
        <time_frame>5 months</time_frame>
        <population>As treated population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>IGRT* 60 Gy in 20 fractions OR IGRT 78 Gy in 39 fractions&#xD;
Image guided external beam radiotherapy with or without brachytherapy boost: image guided external beam radiotherapy (IGRT) or IGRT with high dose rate (HDR) brachytherapy boost</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>IGRT 37.5 Gy in 15 fractions&#xD;
+ HDR brachytherapy boost 15 Gy&#xD;
Image guided external beam radiotherapy with or without brachytherapy boost: image guided external beam radiotherapy (IGRT) or IGRT with high dose rate (HDR) brachytherapy boost&#xD;
Brachytherapy: Brachytherapy boost</description>
          </group>
        </group_list>
        <measure>
          <title>Radiotherapy Quality Assurance -Timing</title>
          <description>The time from the the time from IGRT Real Time Review Signed to IGRT Real Time Review Uploaded.</description>
          <population>As treated population.</population>
          <units>Day</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="0" upper_limit="12"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm 1</title>
          <description>IGRT* 60 Gy in 20 fractions OR IGRT 78 Gy in 39 fractions&#xD;
Image guided external beam radiotherapy with or without brachytherapy boost: image guided external beam radiotherapy (IGRT) or IGRT with high dose rate (HDR) brachytherapy boost</description>
        </group>
        <group group_id="E2">
          <title>Arm 2</title>
          <description>IGRT 37.5 Gy in 15 fractions&#xD;
+ HDR brachytherapy boost 15 Gy&#xD;
Image guided external beam radiotherapy with or without brachytherapy boost: image guided external beam radiotherapy (IGRT) or IGRT with high dose rate (HDR) brachytherapy boost&#xD;
Brachytherapy: Brachytherapy boost</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limited follow up time, delayed side effect might not be captured.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Keyue Ding</name_or_title>
      <organization>Canadian cancer trials group</organization>
      <phone>1-613-533-6000 ext 77705</phone>
      <email>kding@ctg.queensu.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

